Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
[EN]The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular d...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/161638 |
| Acceso en línea: | http://hdl.handle.net/10366/161638 |
| Access Level: | acceso abierto |
| Palabra clave: | body mass index estimated glomerular filtration rate glomerular disease proteinuria Sodium Diabetes Mellitus Glucose Proteinuria Glomerulonephritis Glomerular Filtration Rate Kidney Diseases glomerulonefritis glucosa diabetes mellitus sodio tasa de filtración glomerular enfermedades renales |
| id |
ES_4281ffcaebbf7bff83b6cd4aa94a90b5 |
|---|---|
| oai_identifier_str |
oai:gredos.usal.es:10366/161638 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.Caravaca-Fontán, FernandoStevens, KatePadrón, MaiteHuerta, AnaMontomoli, MarcoVilla, JuanGonzález, FaynaVega, CristinaLópez Mendoza, ManuelFernández, LoretoShabaka, AmirRodríguez-Moreno, AntolinaMartín-Gómez, AdoraciónLabrador, Pedro JMolina Andújar, AliciaPrados Soler, M CarmenMartín-Penagos, LuisYerovi, EstefaníaMedina Zahonero, LauraDe La Flor, José CarlosMon, CarmenIbernon, MeritxellRodríguez Gómez, AstridMiquel, RosaSierra, MilagrosMascarós, VictoriaLuzardo, LeonellaPapasotiriou, MariosArroyo, DavidVerdalles, ÚrsulaMartínez-Miguel, PatriciaRamírez-Guerrero, GonzaloPampa-Saico, SaúlMoral Berrio, EsperanzaCanga, José Luis PérezTarragón, BlancaFraile Gómez, María PilarRegidor, DabaibaRelea, JavierXipell, MarcAndrades Gómez, CristinaNavarro, MarujaÁlvarez, ÁlvaroRivas, BegoñaQuintana, Luis FGutiérrez, EduardoPérez-Valdivia, Miguel ÁngelOdler, BalazsKronbichler, AndreasGeddes, ColinAnders, Hans-JoachimFloege, JürgenFernández-Juárez, GemaPraga, Manuelbody mass indexestimated glomerular filtration rateglomerular diseaseproteinuriaSodiumDiabetes MellitusGlucoseProteinuriaGlomerulonephritisGlomerular Filtration RateKidney Diseasesglomerulonefritisproteinuriaglucosadiabetes mellitussodiotasa de filtración glomerularenfermedades renales[EN]The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation. Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by -35%, -41%, -45% and -48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by -6%, -3%, -8% and -10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30-0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: -3.7 versus -5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good. The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction.OXFORD UNIV PRESS202520252023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10366/161638reponame:GREDOS. Repositorio Institucional de la Universidad de Salamancainstname:Universidad de Salamanca (USAL)Inglésinfo:eu-repo/semantics/openAccessoai:gredos.usal.es:10366/1616382026-06-07T06:28:51Z |
| dc.title.none.fl_str_mv |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| title |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| spellingShingle |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Caravaca-Fontán, Fernando body mass index estimated glomerular filtration rate glomerular disease proteinuria Sodium Diabetes Mellitus Glucose Proteinuria Glomerulonephritis Glomerular Filtration Rate Kidney Diseases glomerulonefritis proteinuria glucosa diabetes mellitus sodio tasa de filtración glomerular enfermedades renales |
| title_short |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| title_full |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| title_fullStr |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| title_full_unstemmed |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| title_sort |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| dc.creator.none.fl_str_mv |
Caravaca-Fontán, Fernando Stevens, Kate Padrón, Maite Huerta, Ana Montomoli, Marco Villa, Juan González, Fayna Vega, Cristina López Mendoza, Manuel Fernández, Loreto Shabaka, Amir Rodríguez-Moreno, Antolina Martín-Gómez, Adoración Labrador, Pedro J Molina Andújar, Alicia Prados Soler, M Carmen Martín-Penagos, Luis Yerovi, Estefanía Medina Zahonero, Laura De La Flor, José Carlos Mon, Carmen Ibernon, Meritxell Rodríguez Gómez, Astrid Miquel, Rosa Sierra, Milagros Mascarós, Victoria Luzardo, Leonella Papasotiriou, Marios Arroyo, David Verdalles, Úrsula Martínez-Miguel, Patricia Ramírez-Guerrero, Gonzalo Pampa-Saico, Saúl Moral Berrio, Esperanza Canga, José Luis Pérez Tarragón, Blanca Fraile Gómez, María Pilar Regidor, Dabaiba Relea, Javier Xipell, Marc Andrades Gómez, Cristina Navarro, Maruja Álvarez, Álvaro Rivas, Begoña Quintana, Luis F Gutiérrez, Eduardo Pérez-Valdivia, Miguel Ángel Odler, Balazs Kronbichler, Andreas Geddes, Colin Anders, Hans-Joachim Floege, Jürgen Fernández-Juárez, Gema Praga, Manuel |
| author |
Caravaca-Fontán, Fernando |
| author_facet |
Caravaca-Fontán, Fernando Stevens, Kate Padrón, Maite Huerta, Ana Montomoli, Marco Villa, Juan González, Fayna Vega, Cristina López Mendoza, Manuel Fernández, Loreto Shabaka, Amir Rodríguez-Moreno, Antolina Martín-Gómez, Adoración Labrador, Pedro J Molina Andújar, Alicia Prados Soler, M Carmen Martín-Penagos, Luis Yerovi, Estefanía Medina Zahonero, Laura De La Flor, José Carlos Mon, Carmen Ibernon, Meritxell Rodríguez Gómez, Astrid Miquel, Rosa Sierra, Milagros Mascarós, Victoria Luzardo, Leonella Papasotiriou, Marios Arroyo, David Verdalles, Úrsula Martínez-Miguel, Patricia Ramírez-Guerrero, Gonzalo Pampa-Saico, Saúl Moral Berrio, Esperanza Canga, José Luis Pérez Tarragón, Blanca Fraile Gómez, María Pilar Regidor, Dabaiba Relea, Javier Xipell, Marc Andrades Gómez, Cristina Navarro, Maruja Álvarez, Álvaro Rivas, Begoña Quintana, Luis F Gutiérrez, Eduardo Pérez-Valdivia, Miguel Ángel Odler, Balazs Kronbichler, Andreas Geddes, Colin Anders, Hans-Joachim Floege, Jürgen Fernández-Juárez, Gema Praga, Manuel |
| author_role |
author |
| author2 |
Stevens, Kate Padrón, Maite Huerta, Ana Montomoli, Marco Villa, Juan González, Fayna Vega, Cristina López Mendoza, Manuel Fernández, Loreto Shabaka, Amir Rodríguez-Moreno, Antolina Martín-Gómez, Adoración Labrador, Pedro J Molina Andújar, Alicia Prados Soler, M Carmen Martín-Penagos, Luis Yerovi, Estefanía Medina Zahonero, Laura De La Flor, José Carlos Mon, Carmen Ibernon, Meritxell Rodríguez Gómez, Astrid Miquel, Rosa Sierra, Milagros Mascarós, Victoria Luzardo, Leonella Papasotiriou, Marios Arroyo, David Verdalles, Úrsula Martínez-Miguel, Patricia Ramírez-Guerrero, Gonzalo Pampa-Saico, Saúl Moral Berrio, Esperanza Canga, José Luis Pérez Tarragón, Blanca Fraile Gómez, María Pilar Regidor, Dabaiba Relea, Javier Xipell, Marc Andrades Gómez, Cristina Navarro, Maruja Álvarez, Álvaro Rivas, Begoña Quintana, Luis F Gutiérrez, Eduardo Pérez-Valdivia, Miguel Ángel Odler, Balazs Kronbichler, Andreas Geddes, Colin Anders, Hans-Joachim Floege, Jürgen Fernández-Juárez, Gema Praga, Manuel |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
body mass index estimated glomerular filtration rate glomerular disease proteinuria Sodium Diabetes Mellitus Glucose Proteinuria Glomerulonephritis Glomerular Filtration Rate Kidney Diseases glomerulonefritis proteinuria glucosa diabetes mellitus sodio tasa de filtración glomerular enfermedades renales |
| topic |
body mass index estimated glomerular filtration rate glomerular disease proteinuria Sodium Diabetes Mellitus Glucose Proteinuria Glomerulonephritis Glomerular Filtration Rate Kidney Diseases glomerulonefritis proteinuria glucosa diabetes mellitus sodio tasa de filtración glomerular enfermedades renales |
| description |
[EN]The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation. Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by -35%, -41%, -45% and -48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by -6%, -3%, -8% and -10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30-0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: -3.7 versus -5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good. The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2025 2025 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10366/161638 |
| url |
http://hdl.handle.net/10366/161638 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
OXFORD UNIV PRESS |
| publisher.none.fl_str_mv |
OXFORD UNIV PRESS |
| dc.source.none.fl_str_mv |
reponame:GREDOS. Repositorio Institucional de la Universidad de Salamanca instname:Universidad de Salamanca (USAL) |
| instname_str |
Universidad de Salamanca (USAL) |
| reponame_str |
GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| collection |
GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869406936695308288 |
| score |
15,812455 |